Fas-mediated apoptosis in seven human prostate cancer cell lines: Correlation with tumor stage

Prostate

Volumn 36, Issue 2, 1998, Pages 92-101

  Hedlund, Tammy E ^a   Duke, Richard C ^b   Schleicher, Mary S ^b   Miller, Gary J ^a,c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

APO 1; CD95; Cell death; Prostatic adenocarcinoma

Indexed keywords

FAS ANTIGEN;

APOPTOSIS; ARTICLE; CANCER STAGING; CELL DEATH; DATA ANALYSIS; FLOW CYTOMETRY; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; REVERSE TRANSCRIPTION; TUMOR GROWTH;

EID: 0031834910     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19980701)36:2<92::AID-PROS4>3.0.CO;2-G     Document Type: Article

References (50)

1. Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE, Veltri RW, Walsh PC, Isaacs JT: Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995;1:473-480.
2. Venner PM: Therapeutic options in treatment of advanced carcinoma of the prostate. Semin Oncol 1990;17:73-77.
3. Kerr JF, Searle J: Deletion of cells by apoptosis during castration-induced involution of the rat prostate. Virchows Arch [B] 1973;13:87-102.
4. Isaacs JT, Lundmo PI, Berges R, Martikainen P, Kyprianou N, English HF: Androgen regulation of programmed death of normal and malignant prostatic cells. J Androl 1992;13:457-464.
5. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-424.
6. Culig Z, Klocker H, Eberle J, Kaspar F, Hobisch A, Cronauer MV, Bartsch G: DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate 1993;22:11-22.
7. Suzuki A, Matsuzawa A, Iguchi T: Down regulation of Bcl-2 is the first step on Fas-mediated apoptosis of male reproductive tract. Oncogene 1996;13:31-37.
8. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-243.
9. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, Li-Weber M, Richards S, Dhein J, Trauth BC, Ponstingl H, Krammer PH: Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 1992;267:10709-10715.
10. Singer GG, Abbas AK: The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1994;1:365-371.
11. Owen-Schaub LB, Radinsky R, Kruzel E, Berry K, Yonehara S: Anti-Fas on nonhematopoietic tumors: Levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res 1994;54:1580-1586.
12. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Moller P: Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993;69: 415-429.
13. French LE, Hahne M, Viard I, Radlgruber G, Zanone R, Becker K, Muller C, Tschopp J: Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996;133:335-343.
14. Takeuchi T, Sasaki Y, Ueki T, Kaziwara T, Moriyama N, Kawabe K, Kakizoe T: Modulation of growth and apoptosis response in PC-3 and LNCaP prostate-cancer cell lines by Fas. Int J Cancer 1996;67:709-714.
15. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA: The LNCaP cell line - A new model for studies on human prostatic carcinoma. Prog Clin Biol Res 1980;37:115-132.
16. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP: LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-1818.
17. Loop SM, Rozanski TA, Ostenson RC: Human primary prostate tumor cell line, ALVA-31: A new model for studying the hormonal regulation of prostate tumor cell growth. Prostate 1993;22:93-108.
18. Iizumi T, Yazaki T, Kanoh S, Kondo I, Koiso K: Establishment of a new prostatic carcinoma cell line (TSU-Pr1). J Urol 1987;137:1304-1306.
19. Muraki J, Addonizio JC, Choudhury MS, Fischer J, Eshghi M, Davidian MM, Shapiro LR, Wilmot PL, Nagamatsu GR, Chiao JW: Establishment of new human prostatic cancer cell line (JCA-1). Urology 1990;36:79-84.
20. Brothman AR, Lesho LJ, Somers KD, Wright GL, Merchant DJ: Phenotypic and cytogenetic characterization of a cell line derived from primary prostatic carcinoma. Int J Cancer 1989;44:898-903.
21. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
22. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF: Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978;21:274-281.
23. Foley GE, Lazarus H, Farber S, Uzma BG, Boone BA, McCarthy RE: Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 1965;18:522-529.
24. Lozzio CB, Lozzio BB: Human chronic myelogenous leukemia cell line with positive Philadelphia chromosome. Blood 1975;45:321-334.
25. Andersson LC, Nilsson K, Gahmberg CG: K562 - A human erythroleukemic cell line. Int J Cancer 1979;23:143-147.
26. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K: Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 1980;26:171-176.
27. Duke RC, Cohen JJ, Boehme SA, Lenardo MJ, Surh CD, Kishimoto H, Sprent J: Morphological, biochemical, and flow cytometric assays for apoptosis. In Coligan JE, Kruisbeck AM, Margulies DH, Shevach EM, Strober W (eds): "Current Protocols in Immunology" Section IV, Unit 3.17. New York: John Wiley and Sons, Inc., 1995:1-33.
28. Duke RC, Witter RZ, Nash PB, Young JD-E, Ojcius DM: Cytolysis mediated by ionophores and pore-forming agents: Role of intracellular calcium in apoptosis. FASEB J 1994;8:237-246.
29. Labarca C, Paigen K: A simple, rapid, and sensitive DNA assay procedure. Anal Biochem 1980;102:344-352.
30. Hedlund TE, Miller GJ: A serum-free defined medium capable of supporting growth of four established human prostatic carcinoma cell lines. Prostate 1994;24:221-228.
31. McGahon AJ, Nishioka WK, Martin SJ, Mahboubi A, Cotter TG, Green DR: Regulation of the Fas apoptotic cell death pathway by Abl. J Biol Chem 1995;270:22625-22631.
32. Takahashi S, Sato N, Takayama S, Ichimiya S, Satoh M, Hyakumachi N, Kikuchi K: Establishment of apoptosis-inducing monoclonal antibody 2D1 and 2D1-resistant variants of human T cell lines. Eur J Immunol 1993;23:1935-1941.
33. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
34. 3 in human prostatic carcinoma cells. In Karr JP, Coffey DS, Smith RB, Tindall DJ (eds): "Molecular and Cellular Biology of Prostate Cancer." New York: Plenum Press 1991:253-259.
35. 3 in seven human prostate carcinoma cell lines. Clin Cancer Res 1995;1:997-1003.
36. Sato T, Irie S, Kitada S, Reed JC: FAP-1: A protein tyrosine phosphatase that associates with Fas. Science 1995;268:411-415.
37. Alnemri ES, Fernandes-Alnemri T, Litwack G: Cloning and expression of four novel isoforms of human interleukin-1 beta converting enzyme with different apoptotic activities. J Biol Chem 1995;270:4312-4317.
38. Wang L, Miura M, Bergeron L, Zhu H, Yuan J: Ich-1, an Ice/ ced-3-related gene, encodes both positive and negative regulators of programmed cell death. Cell 1994;78:739-750.
39. Cerretti DP, Kozlosky CJ, Mosley B, Nelson N, Van Ness K, Greenstreet TA, March CJ, Kronheim SR, Druck T, Cannizzaro LA, Huebner K, Black RA: Molecular cloning of the interleukin-1 beta converting enzyme. Science 1992;256:97-100.
40. Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, Kiefer MC, Umansky SR, Glover RA, Cohen MB: Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997;57:1758-1768.
41. Uslu R, Borsellino N, Frost P, Garban H, Ng C, Mizutani Y, Belldegrun A, Bonavida B: Chemosensitization of human prostate carcinoma cell lines to anti-Fas-mediated cytotoxicity and apoptosis. Clin Cancer Res 1997;3:963-972.
42. Stanger BZ, Leder P, Lee TH, Kim E, Seed B: RIP: A novel protein containing a death domain that interacts with Fas/ APO-1 (CD95) in yeast and causes cell death. Cell 1995;81:513-523.
43. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Schevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM: FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996;85:817-827.
44. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM: FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995;81:505-512.
45. Fernandes-Alnemri T, Litwack G, Alnemri ES: CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem 1994;269:30761-30764.
46. Orth K, O'Rourke K, Duan H, Poiriers GG, Dixit VM: Molecular ordering of the cell death pathway. Bcl-2 and Bcl-xL function upstream of the CED-3-like apoptotic proteases. J Biol Chem 1996;271:4573-4576.
47. Armstrong RC, Aja T, Xiang J, Gaur S, Krebs JF, Hoang K, Bai X, Korsmeyer SJ, Karanewsky DS, Fritz LC, Tomaselli KJ: Fas-induced activation of the cell death-related protease CPP32 is inhibited by Bcl-2 and by ICE family protease inhibitors. J Biol Chem 1996;271:16850-16855.
48. Shimizu S, Eguchi Y, Kamiike W, Matsuda H, Tsujimoto Y: Bcl-2 expression prevents activation of the ICE protease cascade. Oncogene 1996;12:2251-2257.
49. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC: Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996;148:1567-1576.
50. Bubendorf L, Sauter G, Moch H, Jordan P, Blochlinger A, Gasser TC, Mihatsch MJ: Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol 1996;148:1557-1565.